Regulation of death and survival in Burkitt"s lymphoma cells
Read Online
Share

Regulation of death and survival in Burkitt"s lymphoma cells

  • 268 Want to read
  • ·
  • 43 Currently reading

Published by University of Birmingham in Birmingham .
Written in English


Book details:

Edition Notes

Thesis (Ph.D) - University of Birmingham, Department of Immunology, Faculty of Medicine and Dentistry.

Statementby Hong Wang.
ID Numbers
Open LibraryOL17163999M

Download Regulation of death and survival in Burkitt"s lymphoma cells

PDF EPUB FB2 MOBI RTF

Introduction. Burkitt lymphoma, a highly aggressive B lymphocyte non‐Hodgkin lymphoma, presents in extranodal and nodal sites 1 and also manifests as B cell acute lymphoblastic leukemia. 2 A characteristic c‐myc oncogene translocation between the long arm of chromosome 8 and the immunoglobulin heavy chain gene on chromosome 14 is seen in 80% of Burkitt lymphoma cases or Cited by: 3. B-cells of the high-grade non-Hodgkin lymphoma Burkitt's lymphoma (BL) overexpress survival oncoproteins, including the proviral integration site for Moloney murine leukaemia virus kinase (Pim)-1, and become apoptosis resistant. Activated death receptor CD95 after ligation with anti-CD95 monoclonal Cited by: 2. About one-half of all Burkitt lymphoma (BL) patients are younger than 40 years, and one-third belong to the adolescent and young adult (AYA) subset, defined by an age between 15 and 25–40 years. Regulation of Bcl-2 family proteins and caspases in cisplatin-treated B-lymphoma cell lines. Akata6 cells were treated with cisplatin (10 μg/ml) in the presence or absence of zVADfmk (50 μ M.

B-cell activation can eventually lead to activation-induced cell death of cancer cells and therefore support anti-cancer treatment. 10 Nevertheless, the TLR9 agonist effects vary strongly between B-cell cancer types, and the responses of B-cell lymphomas to ODN CpG show high variability. 11 Thus, the effects of CpG ODNs on B-cell. Adult Burkitt‐type lymphoma (BL) and acute lymphoblastic leukemia (B‐ALL) are rare entities accounting for 1% to 5% of non‐Hodgkin lymphomas (NHL) or ALL. 1, 2 BL and B‐ALL are composed of high‐grade rapidly proliferating small noncleaved mature B lymphoid cells with propensity for central nervous system (CNS) involvement. B‐ALL is characterized by L3 morphology according to the. There are 2 types of lymphycytes: T cells and B cells. Burkitt’s lymphoma is a fast-growing non-Hodgkin’s lymphoma that originates from B cells. Statistics on Burkitt’s lymphoma. Burkitt’s lymphoma is a relatively rare disease in Western countries, but is common in Central Africa. It makes up % of all non-Hodgkin’s Lymphoma. Programmed cell death ([PCD][1]) in multicellular organisms is a vital process in growth, development, and stress responses that contributes to the formation of tissues and organs. Although numerous studies have defined the molecular participants in apoptotic and [PCD][1] cascades, successful identification of early master regulators that target specific cells to live or die is limited.

  As B cell lymphoma is closely associated with expression of Bcl-2 family proteins, several pro- and anti-apoptotic proteins were analyzed in EBV + cells with interrupted Vav1 expression. The pro-survival and pro-apoptotic Bcl-2 family proteins were examined by Western Blot for cells transduced with shCtrl or shVav1 respectively (Fig. 2A).Among those, Bim expression presented a pattern. The tumor arises from a germinal-center B cell that, in the majority of cases, has acquired a t(14;18) translocation that deregulates BCL2, a key gene in the regulation of cell death. B-cell lymphomas arise at distinct stages of cellular development and maturation, potentially influencing antigen (Ag) presentation and T-cell recognition. Burkitt lymphoma (BL) is a highly malignant B-cell tumor associated with Epstein-Barr Virus (EBV) infection. Although BL can be effectively treated in adults and children, leading to high survival rates, its ability to mask itself from the.   Caspase-independent cell death may have a critical role to play in the therapeutic destruction of tumours. Recently it has been suggested that one of the mechanisms by which rituximab, a therapeutic anti-CD20 antibody, kills B cells is caspase-independent. In this study we show that rituximab can induce death in a variety of Burkitt lymphoma derived cell lines.